Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared
to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through
Visit 9 (Week 32, End of Study).